Pfizer gets USFDA approval for Fragmin to treat blood clot in pediatric patients Farhat Nasim19 May 2019 9:45 AM ISTThe efficacy of Fragmin in children was based on a single trial with 38 pediatric patients with symptomatic deep vein thrombosis and/or pulmonary...
AstraZeneca, Daiichi Sankyo breast cancer drug Trastuzumab Deruxtecan shows promise Medical Dialogues Bureau10 May 2019 9:00 AM ISTThe treatment Trastuzumab Deruxtecan, or DS-8201, demonstrated a clinically meaningful response in patients with refractory HER2-positive metastatic...
AstraZeneca Q1 sales beat estimates on cancer drugs Garima28 April 2019 9:15 AM ISTAstraZeneca, fresh off an oncology deal with Japan's Daiichi Sankyo Co Ltd, in February reported annual sales growth for the first time since 2009,...
Emcure launches generic Eribulin at 40 percent lower price in India Farhat Nasim4 April 2019 9:30 AM ISTEmcure Pharmaceuticals will manufacture Eribulin at its plant at Hinjewadi in Pune and market it at a cost which will be approximately 40 per cent...
Biocon appoints Christiane Hamacher as CEO of Biocon Biologics India Farhat Nasim2 March 2019 11:00 AM IST"Christiane joins us at a critical inflexion point in the business as we build our stature in the large and growing opportunity for biosimilar...
NPPA likely to cap retailer margins of 73 cancer and rare disease drugs: Report Meghna A Singhania21 Feb 2019 3:13 PM ISTHowever, the move is likely to stimulate retailers to spend more as trade margins on drugs that have somehow bypassed the list and the retailers may...
Lupin and AbbVie announces partnership to develop, commercialize Novel Oncology Drug Medical Dialogues Bureau24 Dec 2018 9:30 AM ISTMumbai: Pharma major Lupin and global biopharmaceutical company AbbVie Inc., announced that AbbVie has licensed Lupin's MALT1 (Mucosa-Associated...
Glenmark expects generics to drive growth over next 3 yrs Ruby Khatun Khatun25 Sept 2017 10:37 AM ISTMumbai: Pharma firm Glenmark Pharmaceuticals has said its pipeline of specialty and innovative products over the next three to four years is expected...
Teva to sell contraceptive brand Paragard in 1.1 billion dollar deal Ruby Khatun Khatun13 Sept 2017 1:43 PM ISTTeva Pharmaceutical Industries, on Monday, agreed to sell its contraceptive brand Paragard to a unit of Cooper Cos for $1.1 billion, on a day the...
GSK bets on pioneering cancer therapy with Adaptimmune deal Ruby Khatun Khatun9 Sept 2017 9:32 AM ISTLONDON: GlaxoSmithKline (GSK) said it has licensed the rights to Adaptimmune's pioneering T-cell therapy program to boost its pipeline in oncology,...
